Eprosartan
Eprosartan
CLINICAL USE
Angiotensin-II antagonist:Hypertension
DOSE IN NORMAL RENAL FUNCTION
300–800 mg daily
PHARMACOKINETICS
Molecular weight                           :520.6 (as mesilate) %Protein binding                           :98 %Excreted unchanged in urine     : <2 (as metabolites) Volume of distribution (L/kg)       :13 litreshalf-life – normal/ESRD (hrs)      :5–9/unchanged DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function Initially 300 mg daily and increase according to response DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unlikely to be dialysed. Dose as in normal renal function HD                     :Not dialysed. Dose as in normal renal functionHDF/high flux   :Not dialysed. Dose as in normal renal functionCAV/VVHD      :Not dialysed. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDsCiclosporin: increased risk of hyperkalaemia and nephrotoxicity Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics Epoetin: increased risk of hyperkalaemia; antagonism of hypotensive effect Lithium: reduced excretion, possibility of enhanced lithium toxicity Potassium salts: increased risk of hyperkalaemia Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
– OTHER INFORMATION
Side effects (e.g. hyperkalaemia, metabolic acidosis) are more common in patients with impaired renal functionClose monitoring of renal function during therapy is necessary in those with renal insufficiencyRenal failure has been reported in association with AT-II antagonists in patients with renal artery stenosis, post renal transplant, and in those with severe congestive heart failure.
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home